Related Experiment Videos
Thromboxane synthase inhibition: implications for prostaglandin endoperoxide metabolism. II. Testing the 'redirection
Abstract:
In the preceding paper we described the characterisation of an acute intravenous challenge model for the evaluation of the effects of thromboxane synthase inhibition (TXSI) on eicosanoid metabolism. Herein we describe the biochemical pharmacology of two TXSI and aspirin in this model. Both TXSI caused significant inhibition of plasma TXB2 in vivo without elevation of 6-oxo-PGF1 alpha levels. Similar results were obtained when combined levels of 6-oxo-PGF1 alpha,13,14 dihydro 6-oxo-PGF1 alpha,13,14 dihydro 6,15-dioxo-PGF1 alpha and 6-oxo-PGE1 were measured as an index of PGI2 biosynthesis (PGI2m). Thus no evidence of in vivo redirection of PGH2 to PGI2 was found. Ex vivo experiments performed in serum gave an apparent stimulation of immunoreactive 6-oxo-PGF1 alpha following TXSI but RPHPLC analysis of extracted serum showed that this stimulation was accounted for by increase in a product co-eluting with [3H]PGF2 alpha. The implications of these findings in relation to TXSI and receptor antagonists are discussed.
Insights
Two thromboxane synthase inhibitors (TXSI) effectively reduced thromboxane B2 (TXB2) without altering prostacyclin (PGI2) biosynthesis in an acute intravenous challenge model. This indicates no shunting of precursors in vivo.
Area of Science:
- Biochemistry
- Pharmacology
- Eicosanoid Metabolism
Background:
- Established an acute intravenous challenge model to study thromboxane synthase inhibition (TXSI).
- Previous work characterized this model for evaluating TXSI effects on eicosanoid metabolism.
Purpose of the Study:
- To investigate the biochemical pharmacology of two TXSI agents and aspirin in the established model.
- To assess the in vivo effects of TXSI on thromboxane and prostacyclin biosynthesis.
Main Methods:
- Administered two TXSI agents and aspirin in an acute intravenous challenge model.
- Measured plasma TXB2 levels as an indicator of thromboxane synthase activity.
- Quantified prostacyclin biosynthesis (PGI2m) using combined levels of 6-oxo-PGF1 alpha and its metabolites.
- Performed ex vivo serum experiments and RPHPLC analysis to validate findings.
Main Results:
- Both TXSI agents significantly inhibited plasma TXB2 in vivo.
- No significant elevation in 6-oxo-PGF1 alpha or PGI2m levels was observed with TXSI treatment.
- Ex vivo experiments showed an apparent increase in 6-oxo-PGF1 alpha, but RPHPLC confirmed this was due to another product.
- No evidence of in vivo redirection of prostaglandin H2 (PGH2) to prostacyclin (PGI2) was found.
Conclusions:
- TXSI effectively inhibits thromboxane biosynthesis in vivo without compensatory increases in PGI2 production.
- The observed ex vivo artifact does not reflect in vivo biochemical changes in PGI2 metabolism.
- Findings support the understanding of TXSI mechanisms and have implications for drug development, including receptor antagonists.